| α4β7 integrin (inflammatory gut-homing leukocytes) |
MAdCAM-1-Fc protein |
DSPE-PEG-maleimide (one-pot) |
Piroxicam-accelerated colitis (PAC) |
80
|
| Inflammatory gut-homing leukocyte targeting |
| Cd3 |
aCD3 mAb (in vitro) |
DSPE-PEG-maleimide (one-pot) |
CD3 phenotype T cell targeting in a tumor environment |
58
|
| aCD3 F(ab′)2 (in vivo) |
| Caveolae |
Plasmalemma vesicle-associated protein (PV1) |
DSPE-PEG maleimide (one-pot) |
X, lung targeting |
81
|
| Lung endothelial cells |
Anti PECAM-1 mAb |
DSPE-PEG-Mal (mal post insertion) |
Lung targeting |
82
|
| DEC205+ murine dendritic cells |
DEC205 scFv |
DSPE-PEG-Mal (one-pot) |
X, spleen isolation after 24h of retro orbital injection |
83
|
| Cd4 |
aCD4 mAb |
DSPE-PEG-Mal (mal post insertion) |
CD4 phenotype T cell targeting |
84
|
| Splenic T cells |
aCD5 |
DSPE-PEG-Mal (mal post insertion) |
Cardiac fibrosis |
85
|
| Antigen specific CD8+T cells |
pMHC1 |
DSPE- PEG2000-mal and conjugation with TCEP |
Pr8 influenza virus |
59
|
| Osteoblast |
CH6 Aptamer |
Ch6-S-S-(SH2)2-OH → CH6-SH with DTT, DSPE-PEG-Mal → DSPE-PEG-CH6 (post insertion mal) |
Metabolic skeletal disorders associated with impaired bone formation (e.g. osteoporosis) |
86
|
| Cerebrovascular of inflamed brain |
VCAM-1 (CD106) |
DSPE-PEG2000 azide |
Glioblastoma (pathological permeability of the BBB) |
96
|
| Neutrophils |
aCD177 |
Peptide H or peptide M-PEG2000-DSPE, m-PEG2000-DSPE |
X |
102
|
| Ly6C + inflammatory leukocytes |
Anti-Ly6C antibodies by ASSET (anchored secondary scFV enabling targeting) |
DSPE-PEG-Ome (one-pot) |
DSS colitis |
60
|
| Cd34 mAB for ASSET evaluation, Ly6C for DSS colitis |
Anti-Ly6C antibodies by ASSET (anchored secondary scFV enabling targeting) |
DSPE-PEG-carboxyl (carboxyl post insertion with EDC and NHS) |
DSS colitis |
61
|
| Ly6C + inflammatory leukocytes |
Anti-Ly6C antibodies by ASSET (anchored secondary scFV enabling targeting) |
DSPE-PEG and ASSET |
DSS colitis |
62
|
| EGFR |
aEGFR (ASSET) |
DSPE-PEG and ASSET |
Tumor |
63
|
